Preliminary Results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT 2) Study
|Study ID||Alternative Stable ID||Type|
Study Datasets 1 dataset.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Patient samples were sequenced by Foundation Medicine, Inc. (Cambridge, MA), using FoundationOne CDx, a comprehensive NGS-based in vitro diagnostic device designed to capture cancer genes.
|Illumina HiSeq 2000||320|